Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Takuya Saito

Child & Adolescent Psychiatry Suginami Medical Doctor

NPI 1659762060 CMS profile 1313376

3-1-8 Hamadayama, Suginami 16800

Open in the dashboard

General payments

$64,532

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Takuya Saito of Suginami is reported in the CMS Open Payments database as having received $64,532 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,092 4
2024 General $6,622 10
2023 General $7,997 13
2022 General $12,442 23
2021 General $18,262 32
2020 General $8,963 9
2019 General $6,154 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Takuya Saito
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Takuya Saito were reported at $4,092. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Takuya Saito Child & Adolescent Psychiatry median Middle half National median
2019 $6,154 $129 $42–$419 $163
2020 $8,963 $81 $28–$226 $114
2021 $18,262 $115 $31–$326 $132
2022 $12,442 $124 $40–$382 $149
2023 $7,997 $130 $45–$420 $160
2024 $6,622 $141 $42–$490 $164
2025 $4,092 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sumitomo Dainippon Pharma Co., Ltd. $57,500 87 payments
  2. Shionogi Inc $7,032 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $43,856 41 payments
  2. Honoraria $11,919 13 payments
  3. Travel and Lodging $4,759 22 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $3,717 4 payments
  5. Food and Beverage $281 16 payments
Products named General payments · program years 2019–2025
  1. LATUDA Cns $34,223 51 payments
  2. Blonanserin Cns $6,154 5 payments
  3. LATUDA Neurology $4,092 4 payments
  4. Blonanserin Cns $3,162 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record